GSK, US HHS team up to develop drugs against antibiotic resistance and bioterrorism
Development of the new antibiotics will receive funding through a public-private partnership. For the initial period of 18 months, HHS will provide $40m and around $200m upon the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.